Mode
Text Size
Log in / Sign up
N/A N=100 Treatment

Comparison of Lasers in the Treatment of Scars

Scar

Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Dec 2017
Primary outcome: Primary: Scar Pain — 1.265; 1.181; 1.048; 1.084 units on a scale — p=0.0492

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Fraxel Laser (Device); CO2 Laser (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Marta Hemmingson-Van Beek
Primary completion
Jan 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Scar Pain
1.265; 1.181; 1.048; 1.084 0.0492 sig
PRIMARY
Scar Itching
1.386; 1.337; 1.084; 1.277 0.0817
PRIMARY
Scar Color
5.622; 5.518; 4.108; 4.313 0.0686
PRIMARY
Scar Stiffness
4.361; 4.518; 3.313; 3.386 0.6278
PRIMARY
Scar Thickness
5.325; 5.145; 3.373; 3.530 0.0848
PRIMARY
Scar Irregularity
6.602; 6.500; 3.3964; 4.084 0.3418
PRIMARY
Overall Opinion
6.695; 6.654; 4.024; 4.207 0.1752
PRIMARY
Patient Satisfaction
0; 0; 2; 3; 10; 9
PRIMARY
Observer Total Score
-0.3238; 0.0586 0.0281 sig

Summary

The purpose of this study is to compare the 1550-nm non-ablative Fraxel laser (referred to as Fraxel Laser in this application) to the ablative 10,600-nm carbon dioxide fractional laser (referred to as CO2 Laser in this application) to determine if one is superior to the other in improving the appearance of scars over a series of three treatments. In addition, the investigators hope to identify a more cost-effective method to improve the appearance of scars caused by surgery or trauma.

Eligibility Criteria

Inclusion Criteria

  • Age 18 or older.
  • Fitzpatrick skin type I-IV.
  • Scars secondary to surgery or trauma.
  • Scar length minimum 4 cm in length.

Exclusion Criteria

  • Scars less than 6 weeks old.
  • History of keloid scarring.
  • Use of isotretinoin currently or within 3 months of enrollment
  • Use of photosensitive medication currently or within 3 months of enrollment.
  • Pregnancy -
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02988622). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search